r.jhannsdttir
TL3 Regular · Parma, IT
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 4 January 2025 · last posted 3d · groups: journal-club
157Posts here
2Topics
0Solutions
986Likes received
710Likes given
27Badges
139Days visited
2.4kPosts read
Stated areas
Recent activity
Full stream-
Programming during a large energy deficit Replied, post #49 · Nutrition & Training › Resistance training · 25 Jul 2026 · 17 likes Cardio and resistance: the interaction between energy-intense cardiovascular training and resistance training is real. Moderate cardio is fine; excessive endurance…
-
Why cagrilintide alone is discussed so much less than in combination — does this still… Replied, post #30 · Compounds › Cagrilintide & amylin analogues · 24 Jul 2026 · 14 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #92 · Nutrition & Training › Protein & intake · 22 Jul 2026 · 4 likes On post #88 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…
-
How shortages have affected compounding permissions Replied, post #58 · Access › Shortages · 21 Jul 2026 · 1 like Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for…
-
What a certificate commits its issuer to Replied, post #45 · Analytics › COA interpretation · 17 Jul 2026 · 23 likes On post #41 — agreed on the reasoning, with one qualification. Purity and content are different measurements: purity tells you what proportion of the detected material…
-
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #85 · Practice › Storage & stability · 9 Jul 2026 · 18 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Revisiting: What pooling buys you and what it destroys Replied, post #84 · Evidence › Meta-analyses · 9 Jul 2026 · 0 likes Why forest plots are more informative than pooled numbers: they show the variation across studies, which tells you whether the effect is consistent or heterogeneous. A…
-
Why side effects reset at each escalation and that is not a failure Replied, post #4 · Practice › Side effects · 7 Jul 2026 · 33 likes I read post #3 twice before replying, because I had assumed the opposite. Nausea: the most common side effect and the most dose- and titration-dependent one. It is…
-
I have no scientific background — can I still follow the analytics categories? Replied, post #34 · Start Here › Welcome · 6 Jul 2026 · 0 likes Coming back to post #32, because the follow-up matters more than the original answer. On the reading order question specifically: start with the how-to-ask materials in…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #49 · Analytics › Home & field testing · 3 Jul 2026 · 0 likes Coming back to post #47, because the follow-up matters more than the original answer. What you can use home tests for: confirmation that a solution contains peptide (as…
-
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #62 · Evidence › Journal club · 29 Jun 2026 · 13 likes Worth separating two things that post #58 runs together. SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes. The first outcome trial in…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #48 · Sourcing › Independent verification · 28 Jun 2026 · 11 likes How to submit a sample: contact the service directly. They will provide instructions on vial type, quantity, labelling, shipping. Following their instructions exactly…
Maintains 4 documents
- STEP 4 — trial digestReview due 29 Apr 2027
- SELECT — trial digestReview due 26 Nov 2026
- SCALE — trial digestReview due 6 May 2027
- Orforglipron phase 2 (obesity) — trial digestReview due 4 Apr 2027